Eurofins BioPharma
Eurofins BioPharma, a leading entity in the bioanalytical and pharmaceutical testing industry, is headquartered in Japan (JP) and operates extensively across Europe and North America. Founded in 1987, the company has established itself as a trusted partner for biopharmaceutical companies, offering a comprehensive suite of services that includes bioanalytical testing, drug development support, and quality control. With a focus on innovation, Eurofins BioPharma distinguishes itself through its advanced methodologies and commitment to regulatory compliance. The company has achieved significant milestones, including numerous accreditations and partnerships that enhance its market position. Renowned for its expertise in pharmacokinetics and toxicology, Eurofins BioPharma continues to play a pivotal role in advancing the biopharmaceutical landscape, ensuring the safety and efficacy of new therapies.
DitchCarbon Score
How does Eurofins BioPharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eurofins BioPharma's score of 10 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eurofins BioPharma's reported carbon emissions
In 2023, Eurofins BioPharma reported total carbon emissions of approximately 529,040,000 kg CO2e. This figure includes 71,965,000 kg CO2e from Scope 1 emissions, 137,199,000 kg CO2e from Scope 2 emissions, and 319,876,000 kg CO2e from Scope 3 emissions. Over the previous years, the company has shown a trend in its emissions data: in 2022, total emissions were about 496,912,000 kg CO2e, with Scope 1 at 62,558,000 kg CO2e, Scope 2 at 122,388,000 kg CO2e, and Scope 3 at 311,966,000 kg CO2e. In 2021, total emissions were approximately 457,527,000 kg CO2e, with Scope 1 at 58,507,000 kg CO2e, Scope 2 at 117,572,000 kg CO2e, and Scope 3 at 281,447,000 kg CO2e. Despite these figures, Eurofins BioPharma has not disclosed specific reduction targets or initiatives as part of its climate commitments. The absence of documented reduction targets suggests that while the company is aware of its carbon footprint, it may not yet have formalised strategies to mitigate its emissions. Overall, Eurofins BioPharma's emissions data highlights the significant impact of Scope 3 emissions, which consistently represent the largest portion of their total emissions. The company operates from its headquarters in Japan and is part of a broader industry context where many organisations are increasingly focusing on sustainability and carbon reduction strategies.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 67,015,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 145,430,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 272,508,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eurofins BioPharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
